Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

Simple item page
dc.contributor.authorWhite, D.
dc.contributor.authorEadie, L.
dc.contributor.authorSaunders, V.
dc.contributor.authorHiwase, D.
dc.contributor.authorHughes, T.
dc.date.issued2013
dc.description.statementofresponsibilityDL White, LN Eadie, VA Saunders, DK Hiwase, and TP Hughes
dc.identifier.citationLeukemia, 2013; 27(5):1201-1204
dc.identifier.doi10.1038/leu.2012.295
dc.identifier.issn0887-6924
dc.identifier.issn1476-5551
dc.identifier.orcidWhite, D. [0000-0003-4844-333X]
dc.identifier.orcidEadie, L. [0000-0003-1912-7602]
dc.identifier.orcidHiwase, D. [0000-0002-6666-3056]
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/78906
dc.language.isoen
dc.publisherNature Publishing Group
dc.rights© 2013 Macmillan Publishers Limited
dc.source.urihttps://doi.org/10.1038/leu.2012.295
dc.subjectK562 Cells
dc.subjectHumans
dc.subjectBenzamides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectProtein Kinase Inhibitors
dc.subjectDrug Interactions
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subjectProton Pump Inhibitors
dc.subjectImatinib Mesylate
dc.titleProton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications